A breakthrough technique utilising Magnetic Resonance Imaging (MRI) is set to optimise the prostate cancer diagnostic and management process.
Led by Melbourne-based urologist, Associate Professor Jeremy Grummet, Australian Urology Associates (AUA Urology), the clinical research sees the field of MRI emerging at the forefront of the diagnostic process – enabling a more accurate and less invasive assessment of the prostate.
Recognised for his outstanding contribution to clinical research, A/Professor Grummet was awarded “Best Abstract in Session” at the recent Urological Association of Asia Congress in Singapore.
“It was a great thrill and terrific that our paper, looking at comparing MRI results compared to radical prostatectomy specimens, was so highly regarded,” said A/Professor Grummet.
“We are leveraging the precision that MRI provides us, in a number of areas. When used in patients prior to radical prostatectomy it enables us to compare accurate imagery with the actual slices of the entire prostate specimen and map the lesions. The high correlation this provides, approximately 80%, adds further strength to the concept of having an MRI early on in diagnostic process.”
The MRI has also been adopted for use before patients have their first biopsy – the imaging enabling clinicians to clearly view the prostate and in many cases avoid a biopsy altogether. As A/Professor Grummet explains, “MRI is not perfect but we think there’s enough evidence to avoid unnecessary biopsies if the MRI is negative. If, however, the MRI is positive and a biopsy is necessary, it allows us to take a very targeted approach.”
This technique is distinct due to the method of biopsy used. Many studies compare results to traditional prostate biopsies where a select number of tissue samples are taken via the rectum. A/Professor Grummet’s research uses the increasingly prevalent transperineal biopsy that can take more cores of tissues and, when combined with thorough sampling of the prostate, provides a highly accurate base from which to compare the MRI results.
“MRI, in combination with transperineal biopsy is crucial as it removes much of the guessing that’s required.”
“We are very grateful indeed for the Clinical Data Analytics Grant we received from Tolmar Australia to support this research and are delighted with the progress we have made,” said A/Prof Grummet.
“Australia is at the forefront of prostate cancer research and leading the world in MRI research, which is very exciting indeed. Much of this would not be possible without the commitment and support we receive,” he concluded.
“Tolmar Australia is absolutely thrilled for A/Professor Grummet and the team at AUA Urology with the progress they have made in MRI research,” said Dieter Torheiden, General Manager, Tolmar Australia.
“The Clinical Data Analytics Grant was awarded to support prostate cancer diagnosis, specifically MRI, and the outcome of the research is absolutely outstanding,” he concluded.